Want to join the conversation?
$MRK announced efficacy and safety data in previously untreated adults with HIV-1 infection for its investigational once-daily formulation of Isentress (raltegravir), known as raltegravir 600 mg, from the ongoing Phase 3 pivotal trial called ONCEMRK. The study found raltegravir is non-inferior efficacy and safety to a regimen.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?